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standard CEA methodology and found the targeted therapeutics
to be cost-effective using generally accepted thresholds. Consid-
ering the signiﬁcance of the value questions regarding cancer care
and the interest of policymakers, more health economic studies
using standard CEA techniques are warranted for targeted oncol-
ogy therapeutics.
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OBJECTIVES: Cetuximab is an inhibitor of the epidermal
growth factor receptor that has been shown in a phase III clinical
trial to be effective when used in combination with radiotherapy
(RT) in patients with locally advanced squamous cell cancers of
the head and neck (LASCCHN). As part of an application to the
Pharmaceutical Beneﬁts Advisory Committee (PBAC) in Austra-
lia, we assessed whether this represents a cost-effective use of
public health resources compared with RT alone for the treat-
ment of patients in whom chemoradiotherapy (RT plus cisplatin)
is not a viable treatment option. METHODS: Data on the com-
parative efﬁcacy of cetuximab plus RT versus RT alone were
sourced from a completed international phase III study. We
applied the comparative efﬁcacy between these therapies
observed in this trial to patients for whom chemoradiotherapy is
not a viable option. These data were incorporated into a cost-
effectiveness analysis taking the perspective of the Australian
health care system. Outcomes were assessed as life years gained
(LYG) based on an arithmetic extrapolation of the trial observed
survival. Costs were restricted to those associated with the con-
comitant administration of eight weeks of cetuximab and RT,
and the treatment of cetuximab related adverse events. All costs
and beneﬁts were discounted at 5% per annum. Costs were
stated in A$ at 2006 prices. RESULTS: The modelled analysis
estimated an incremental gain in average survival of 7.2 months.
This was achieved at an average incremental cost of A$18,404.
The resulting cost per LYG was estimated to be A$32,910. CON-
CLUSION: This analysis resulted in a positive recommendation
from the PBAC to fund cetuximab for patients with LASCCHN
on the basis of acceptable cost-effectiveness. The outcome of
current trials assessing the beneﬁts of cetuximab and chemorad-
iotherapy will further establish the role of this therapy in patients
with head and neck cancer.
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OBJECTIVES: To assess the cost-effectiveness of switching to
exemestane vs. continued tamoxifen therapy for early-stage
breast cancer, a markov model was developed. Exemestane has
become a widely used medication to treat women with breast
cancer. Medical studies showed that switching to exemestane
may be effective looking at overall survival. No cost-effectiveness
study of exemestane has been conducted for the German health
care context to date. METHODS: Different markov health states
were based on clinical data from the Intergroup-Exemestane-
Study (IES). Seven different health states were included from no
recurrence over local and distant recurrences to death. In addi-
tion, several adverse events (osteoporosis, endometrial cancer,
thromboembolism etc.) were factored in. The model population
was set as postmenopausal women, who are in remission from
early stage breast cancer receiving two to three years of adjuvant
treatment with tamoxifen at the time of model entry. Upon model
entry either a continuing daily therapy with 20 mg tamoxifen or
a switch to 25 mg exemestane for the next two to three years
takes place. The model takes a German health care perspective.
The cycle length is set at six months, lasting for up to 38 years.
Speciﬁc German mortality data was applied. Costs and beneﬁts
were discounted at 5%. Results were thoroughly tested in
deterministic and a probabilistic sensitivity-analysis. RESULTS:
Total incremental costs of exemestane on a lifetime basis
are EUR4,195.52, resulting in an incremental cost ratio of
EUR17,632.82 per additional QALY, or EUR16,857.85 per life-
year gained. Incremental costs per disease-free year of survival
are EUR12,851.35. Sensitivity analyses showed the stability of
these results. CONCLUSION: Compared to tamoxifen mono-
therapy the switch to exemestane after two to three years of
tamoxifen therapy resulted to be a cost-effective strategy in adju-
vant therapy for early-stage breast cancer in postmenopausal
women within the German health care context.
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OBJECTIVES: In Ireland every year, approximately 18,000
women receive abnormal smear results, 1300 are diagnosed with
carcinoma in situ, 200 with cervical cancer and 70 die from the
disease. The objective of this study was to estimate the impact of
implementing prophylactic cervical cancer (CC) vaccination, in
Ireland, on CC morbidity and mortality and its cost effectiveness
from an Irish health care perspective. METHODS: A static
Markov cohort model with 12 different health states was used.
Transition probabilities and utility values were obtained from
the literature. Costs were obtained from an Irish speciﬁc study.
Under the base case: vaccine coverage was 100%; 49% and 28%
of the population undertook regular and irregular screening
respectively; and the price of the vaccine was set at price parity
with a quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)
recombinant vaccine. Costs and beneﬁts were discounted at
3.5%. Sensitivity analyses were undertaken to examine the main
variables affecting cost effectiveness. RESULTS: Vaccinating 12
year old girls was predicted by the model to reduce the number
of cases and deaths from cervical cancer by 67%. Prophylactic
cervical cancer vaccination was cost effective at an incremental
cost of €24,261 per QALY. Results were most sensitive to the
total cost of vaccination, longevity of protection and discount
rates. If administration and GP fees of €150 are taken into
account incremental costs increase to €35,819 per QALY. A
booster vaccine at age 22 and discounting beneﬁts at 3% result in
incremental costs per QALY of €29,723 and €19,117 per QALY
respectively. CONCLUSION: Implementing prophylactic cervi-
cal cancer vaccination in Ireland is a cost effective way to reduce
cervical cancer morbidity and mortality. However, cost effective-
ness is sensitive to the longevity of protection and the total cost
of vaccination.
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